Octagon Capital Advisors LP Has $15.74 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Octagon Capital Advisors LP lifted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 154.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 668,000 shares of the company's stock after buying an additional 405,274 shares during the quarter. Dyne Therapeutics comprises approximately 2.6% of Octagon Capital Advisors LP's investment portfolio, making the stock its 15th biggest holding. Octagon Capital Advisors LP owned about 0.66% of Dyne Therapeutics worth $15,738,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Millennium Management LLC raised its holdings in shares of Dyne Therapeutics by 526.5% in the fourth quarter. Millennium Management LLC now owns 37,536 shares of the company's stock valued at $884,000 after purchasing an additional 31,545 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Dyne Therapeutics by 5.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,580 shares of the company's stock valued at $1,263,000 after buying an additional 2,903 shares in the last quarter. Integral Health Asset Management LLC acquired a new position in Dyne Therapeutics during the fourth quarter worth $3,534,000. Janus Henderson Group PLC raised its position in Dyne Therapeutics by 8.3% during the fourth quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company's stock worth $173,808,000 after acquiring an additional 566,146 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in shares of Dyne Therapeutics in the 4th quarter valued at about $42,408,000. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $12.56 on Tuesday. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -3.53 and a beta of 1.19. The company has a 50-day simple moving average of $10.38 and a 200-day simple moving average of $17.85. Dyne Therapeutics, Inc. has a one year low of $6.36 and a one year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). As a group, research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DYN has been the topic of a number of analyst reports. Royal Bank of Canada restated an "outperform" rating and set a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Chardan Capital reiterated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Friday. JPMorgan Chase & Co. reduced their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. HC Wainwright dropped their price target on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a research note on Friday. Finally, Piper Sandler lowered their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $46.85.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now owns 199,087 shares of the company's stock, valued at $2,777,263.65. The trade was a 1.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders sold 6,237 shares of company stock worth $77,760. Insiders own 14.14% of the company's stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.